WVE: Durable RNA editing and innovative obesity trials drive clinical and regulatory progress in 2024
RNA editing has advanced with highly specific, durable correction in clinical programs like AATD and PNPLA3, supported by chemistry innovations and new trial designs. The Inhibin E program is progressing in obesity and cardiometabolic disease, with data and regulatory milestones expected this year…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.